Communiqués Eli Lilly and Company

Actions

LLY

US5324571083

Produits pharmaceutiques

Marché Fermé - NYSE Autres places de cotation 22:05:15 21/07/2026			Varia. 5j.	Varia. 1 janv.
1 175,41 ^USD	+2,49 %		+1,98 %	+9,37 %

05:12	Novo Nordisk poursuit Eli Lilly aux États-Unis pour publicité mensongère concernant le Zepbound et le Mounjaro	MT
03:55	REVUE DE PRESSE - Financial Times - 22 juillet	RE

Communiqués

21/07	Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates	PR
16/07	Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions	PR
16/07	Pharmaceutical Method-Of-Use Claims After Teva v. Eli Lilly And In Re Xencor: Written Description, Enablement, And The Known-Compound Genus	AQ
09/07	/C O R R E C T I O N -- Eli Lilly and Company/	PR
01/07	Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios in Mainland China	AQ
26/06	Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy	PR
25/06	What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management	PR
24/06	Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders	PR
24/06	OURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options	AQ
22/06	Lilly declares third-quarter 2026 dividend	PR
14/06	Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL	PR
13/06	Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting	PR
10/06	Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable	PR
10/06	FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis	PR
08/06	Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials	PR
07/06	Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause	PR
06/06	Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications	PR
03/06	Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association Annual Meeting	AQ
02/06	Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting	PR
01/06	Lilly's Retevmo demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer	AQ
31/05	Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer	PR
29/05	Eli Lilly and Company - Foundayo and Zepbound now covered for millions of Americans	AQ
28/05	Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care	PR
28/05	Foundayo and Zepbound now covered for millions of Americans	PR
27/05	Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference	PR